DFTX — Definium Therapeutics, Inc. stock price, charts and financials
QT91Definium Therapeutics, Inc.Definium Therapeutics, Inc. (NASDAQ: DFTX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
42.32
+0.53+1.27%
Earnings
Up 1.3% — Earnings due 2026-08-06 — pre-report positioning.
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 19.31% | Shs Outstand | 109.06M | Perf Week | 0.86% |
| Market Cap | 4.62B | Forward P/E | - | EPS next Y | -1.59 | Insider Trans | -0.48% | Shs Float | 107.20M | Perf Month | -4.53% |
| Enterprise Value | 4.45B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 9.93% | Perf Quarter | 94.57% |
| Income | -184.00M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 3.68 | Perf Half Y | 132.14% |
| Sales | 0.00 | P/B | 35.23 | EPS next Y | 27.54% | ROA | -59.19% | Short Interest | 10.64M | Perf YTD | 216.06% |
| Book/sh | 1.20 | P/C | 22.08 | EPS next 5Y | - | ROE | -102.48% | 52W High | 49.20 -13.98% | Perf Year | 401.42% |
| Cash/sh | 1.92 | P/FCF | - | EPS past 3/5Y | - | ROIC | -60.39% | 52W Low | 8.59 392.67% | Perf 3Y | 870.64% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 4.48% 5.85% | Perf 5Y | -7.50% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -1566.67% | Oper. Margin | 0.00% | ATR (14) | 2.55 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.69 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 52.52 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.69 | EPS Q/Q | -102.86% | SMA20 | -3.93% | Beta | 2.24 | Target Price | 55.75 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | 17.17% | Rel Volume | 0.67 | Prev Close | 41.79 |
| Employees | 105 | LT Debt/Eq | 0.09 | Earnings | Aug 06 | SMA200 | 97.72% | Avg Volume | 2.79M | Price | 42.32 |
| IPO Date | Nov 15, 2016 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -44.27% - | Net Debt/EBITDA | 1.18 | Volume | 1,861,961 | Change | 1.27% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-27-26 | Initiated | Wells Fargo | Overweight | $68 |
| Jul-24-26 | Reiterated | Piper Sandler | Overweight | $48 → $73 |
| Jul-08-26 | Reiterated | Stifel Nicolaus | $30 → $60 | |
| Jun-30-26 | Reiterated | Canaccord Genuity | Buy | $60 → $58 |
| Jun-23-26 | Reiterated | Needham | Buy | $28 → $50 |
| Jun-22-26 | Reiterated | Canaccord Genuity | Buy | $38 → $60 |
| Jun-22-26 | Reiterated | Leerink Partners | Outperform | $52 |
| Jun-22-26 | Reiterated | Oppenheimer | Outperform | $40 → $60 |
| May-08-26 | Reiterated | Piper Sandler | Overweight | $49 → $48 |
| Apr-23-26 | Reiterated | Oppenheimer | $25 → $40 |
Latest News
Aug-03-26
Jul-31-26
Jul-31-2610:56AM
Jul-30-26
Jul-30-2604:01PM
Jul-27-26
Jul-27-2608:45AM
Jul-20-26
Jul-16-26
07:00AM
Jul-14-26
Jul-14-2610:56AM
07:07AM
07:00AM
Jul-08-26
Jul-06-26
Jun-25-26
Jun-25-2609:55AM
Jun-24-26
Jun-24-2602:19PM
Jun-23-26
Company
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 8/31/2019 | FY 2018 8/31/2018 | FY 2017 8/31/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Gross Profit | 0 | -1 | -3 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 49 | 39 | 42 | 30 | 59 | 14 | 0 | 1 | 1 | |
| Research and Development | 118 | 65 | 49 | 36 | 35 | 19 | 0 | 0 | 0 | |
| Other Operating Expense | -1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Operating Income | -166 | -104 | -94 | -66 | -94 | -33 | 0 | -1 | -1 | |
| Interest Expense | 5 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -12 | -2 | -1 | 11 | 0 | -1 | -1 | 0 | 0 | |
| Net Income Before Taxes | -184 | -109 | -96 | -57 | -94 | -34 | -1 | -1 | -1 | |
| Income Taxes | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -184 | -109 | -96 | -57 | -93 | -34 | -1 | -1 | -1 | |
| Net Income From Continuing Operations | -184 | -109 | -96 | -57 | -93 | -34 | -1 | -1 | -1 | |
| Net Income | -184 | -109 | -96 | -57 | -93 | -34 | -1 | -1 | -1 | |
| EPS (Recurring) | -2.06 | -1.54 | -2.44 | -1.53 | -3.40 | -1.92 | -2.94 | -2.74 | -4.85 | |
| EPS (Basic, Before Extraordinaries) | -2.06 | -1.54 | -2.44 | -1.53 | -3.40 | -1.92 | -2.94 | -2.74 | -4.85 | |
| EPS (Diluted) | -2.06 | -0.15 | -2.44 | -1.53 | -3.40 | -1.92 | -2.94 | -2.74 | -4.85 | |
| EBITDA | -178 | -106 | -93 | -52 | -91 | -34 | -1 | -1 | -2 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 89 | 70 | 39 | 31 | 27 | 18 | 0 | 0 | 0 | |
| Market Capitalization | 1,192 | 487 | 143 | 68 | 559 | 824 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Roberts Brandi | Chief Financial Officer | Jun 25 '26 | Sale | 45.03 | 3,013 | 135,675 | 209,487 | Jun 26 |
| Barrow Robert | Chief Executive Officer | Jun 25 '26 | Sale | 45.03 | 29,208 | 1,315,236 | 1,098,246 | Jun 26 |
| Karlin Daniel | Chief Medical Officer | Jun 25 '26 | Sale | 45.03 | 10,035 | 451,876 | 503,282 | Jun 26 |
| Wiley Matthew T. | Chief Commercial Officer | Jun 25 '26 | Sale | 45.03 | 2,867 | 129,101 | 174,633 | Jun 26 |
| Sullivan Mark | Chief Legal Officer | Jun 25 '26 | Sale | 45.03 | 13,008 | 585,750 | 320,571 | Jun 26 |
| Karlin Daniel | Chief Medical Officer | Mar 25 '26 | Sale | 18.47 | 8,018 | 148,092 | 413,317 | Mar 26 |
| Sullivan Mark | Chief Legal Officer | Mar 25 '26 | Sale | 18.47 | 10,702 | 197,666 | 271,079 | Mar 26 |
| Barrow Robert | Chief Executive Officer | Mar 25 '26 | Sale | 18.47 | 24,431 | 451,241 | 752,454 | Mar 26 |
| Karlin Daniel | Chief Medical Officer | Dec 26 '25 | Sale | 13.15 | 5,600 | 73,623 | 425,025 | Dec 29 |
| Barrow Robert | Chief Executive Officer | Dec 26 '25 | Sale | 13.15 | 25,791 | 339,072 | 778,477 | Dec 29 |
| Sullivan Mark | Chief Legal Officer | Dec 26 '25 | Sale | 13.15 | 11,276 | 148,244 | 282,576 | Dec 29 |
| Sullivan Mark | Chief Legal Officer | Sep 25 '25 | Sale | 9.77 | 11,278 | 110,186 | 293,852 | Sep 26 |
| Barrow Robert | Chief Executive Officer | Sep 25 '25 | Sale | 9.77 | 25,797 | 252,037 | 804,268 | Sep 26 |
| Karlin Daniel | Chief Medical Officer | Sep 25 '25 | Sale | 9.77 | 7,704 | 75,268 | 430,625 | Sep 26 |
| Sullivan Mark | Chief Legal Officer | Jun 25 '25 | Sale | 6.80 | 11,491 | 78,139 | 305,130 | Jun 26 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.